Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 6, 2017
SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), at the 2...
Aug 29, 2017
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will participate in the following investor conferences in September: Liolios Gateway Conference - Presenting on Wednesday, September 6 at 10:00 a.m. PDT / 1:00 p.m. EDT in San Francisco Wells F...
Aug 22, 2017
SAN DIEGO, Aug. 22, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), on Augus...
Jul 31, 2017
SAN DIEGO, July 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the underwriters of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share have exercised in full their option to purchase an additional 937,500 shares. All of t...
Jul 12, 2017
SAN DIEGO, July 12, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share.  All of the shares are being sold by Arena.  The gross proceeds from the offering are expected to be $150.0 million, ...
Jul 11, 2017
SAN DIEGO, July 11, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in an underwritten public offering.  Arena expects to grant the underwriters an option to purchase up to an additional $22.5 milli...
Jul 10, 2017
SAN DIEGO, July 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension (PAH).  In this 61-patient study, the primary efficacy ...
Jun 29, 2017
SAN DIEGO, June 29, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the completion of a Phase 1 comparative bioavailability study evaluating the pharmacokinetic (PK) profile of extended release (XR) ralinepag compared to the immediate release (IR) formulation in healthy adults. While the IR formulation curren...
Jun 15, 2017
SAN DIEGO, June 15, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 21, at 1:30 p.m. EDT. The conference will take place June 20-21, 2017, at the St...
Jun 14, 2017
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that at the annual meeting of stockholders, held June 13, 2017, stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company's certificate of incorporation to effect a reverse stock split of Arena's...
Jun 14, 2017
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the appointment of Jennifer Jarrett to the Company's Board of Directors.  Ms. Jarrett has over 20 years of experience as a senior executive and finance professional in the life sciences industry.  "We are excited to have someone with Jennife...
Jun 1, 2017
SAN DIEGO, June 1, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will present a corporate update at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:30am EDT. The conference will take place June 6-9, 2017 at the Grand Hyatt New York in New York City....
May 18, 2017
SAN DIEGO, May 18, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused on the treatment of pulmonary arterial hypertension (PAH) in New York City on Thursday, May 25, from 8-9:30 a.m. EDT. The meeting will feature presentations by key opinio...
May 16, 2017
SAN DIEGO, May 16, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), on May 23 at the American Thoracic Society (ATS) 2017 Inte...
Apr 21, 2017
SAN DIEGO, April 21, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of its previously announced underwritten public offering of 69,000,000 shares of its common stock, including 9,000,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters.  All of the shares w...
Page:
...
Next Last
 
= add release to Briefcase